Literature DB >> 14597972

High molecular weight kininogen and factor XII binding to endothelial cells and astrocytes.

Lawrence P Fernando1, Snehlatha Natesan, Kusumam Joseph, Allen P Kaplan.   

Abstract

We have quantitated the binding of high molecular weight kininogen (HK) to human microvascular endothelial cells of lung and dermal origin as well as to astrocytes and compared the results with those reported for human umbilical vein endothelial cells (HUVEC). We also reassessed parameters of binding to HUVEC employing cells in suspension as well as cells attached to the culture plate and report similar numbers of sites varying from 6.96x10(5) to 7.71x10(5) per cell. The present study shows that HK binds with high specificity and affinity to microvascular endothelial cells (Kd = 1.86 to 4.5 nM) compared to HUVEC (Kd = 10.35 nM) but with lower affinity to astrocytes (Kd = 23.73 nM). Human cytokeratin 1, urokinase plasminogen activator receptor and gC1qR were found to be HK binding proteins present at the surface of microvascular endothelial cells and astrocytes analogous to that seen in HUVEC, as assessed by inhibition of binding with antibody to each protein. Lung microvascular endothelial cells had approximately half the number of HK binding sites as HUVEC while dermal micro vascular endothelial cells and astrocytes had only 8-10% of the sites/cell. The affinity of binding to the microvascular endothelial cells was greater than HUVEC, the affinity of binding to astrocytes was considerably less, nevertheless binding to each cell type involves gC1qR, cytokeratin 1 and u-PAR to varying degrees. We also demonstrate, for the first time, that factor XII binds to all of these cell types in a saturable and Zn(+2) dependent manner. Given that factor XII accelerates the interactions among cell surfaces and proteins of the contact activation cascade to generate bradykinin, binding of factor XII (and the prekallikrein-HK complex) may serve as a mechanism by which these proteins are concentrated locally to facilitate their interactions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14597972     DOI: 10.1160/TH03-04-0231

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

Review 1.  In vivo roles of factor XII.

Authors:  Thomas Renné; Alvin H Schmaier; Katrin F Nickel; Margareta Blombäck; Coen Maas
Journal:  Blood       Date:  2012-09-19       Impact factor: 22.113

2.  gC1qR Antibody Can Modulate Endothelial Cell Permeability in Angioedema.

Authors:  Marina Fandaros; Kusumam Joseph; Allen P Kaplan; David A Rubenstein; Berhane Ghebrehiwet; Wei Yin
Journal:  Inflammation       Date:  2021-09-07       Impact factor: 4.092

3.  Hepatitis C virus core protein induces neuroimmune activation and potentiates Human Immunodeficiency Virus-1 neurotoxicity.

Authors:  Pornpun Vivithanaporn; Ferdinand Maingat; Liang-Tzung Lin; Hong Na; Christopher D Richardson; Babita Agrawal; Eric A Cohen; Jack H Jhamandas; Christopher Power
Journal:  PLoS One       Date:  2010-09-21       Impact factor: 3.240

Review 4.  Science review: searching for gene candidates in acute lung injury.

Authors:  Dmitry N Grigoryev; James H Finigan; Paul Hassoun; Joe G N Garcia
Journal:  Crit Care       Date:  2004-06-30       Impact factor: 9.097

5.  Kinin Peptides Enhance Inflammatory and Oxidative Responses Promoting Apoptosis in a Parkinson's Disease Cellular Model.

Authors:  Anna Niewiarowska-Sendo; Andrzej Kozik; Ibeth Guevara-Lora
Journal:  Mediators Inflamm       Date:  2016-09-18       Impact factor: 4.711

Review 6.  Pharmacological Tools to Activate Microglia and their Possible use to Study Neural Network Patho-physiology.

Authors:  Fernando Pena-Ortega
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

7.  The Role of Bradykinin Receptors in Hereditary Angioedema Due to C1-Inhibitor Deficiency.

Authors:  Wojciech Dyga; Aleksander Obtulowicz; Tomasz Mikolajczyk; Anna Bogdali; Pawel Dubiela; Krystyna Obtulowicz
Journal:  Int J Mol Sci       Date:  2022-09-07       Impact factor: 6.208

8.  Hereditary angioedema therapy: kallikrein inhibition and bradykinin receptor antagonism.

Authors:  Marc Riedl
Journal:  World Allergy Organ J       Date:  2010-09       Impact factor: 4.084

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.